REVEL A randomized double blind phase III study of docetaxel DOC and ramucirumab RAM IMC 1121B versus DOC and placebo PL in the treatment of stage IV non small cell lung cancer NSCLC following disease progression after one prior platinum based therapy
Bildiriler > Özet Bildiri · 2014
Yazarlar: M Perol, TE Ciuleanu, O Arrieta, K Prabhash, KN Syrigos, Tuncay GÖKSEL, K Park, RD Kowalyszyn, J KKowalyszyn, G Czyzewicz, S Czyzewicz, CR Lewanski, E Alexandris, A Zimmerman, N Chouaki, WJ John, S Yurasov, EB Garon
0th Annual Meeting of the American Society of Clinical Oncology, Amerika Birleşik Devletleri, Uluslararası, Özet Bildiri, 2014-2014